PRESSEPORTAL Presseportal Logo

mehr Themen

Folgen
Keine Story von Avectas mehr verpassen.
Warum muss ich meine Email-Adresse eingeben?

Avectas

Filtern
  • 10.05.2021 – 08:01

    Avectas announces publication in leading cell therapy journal Cytotherapy of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy applications'

    Dublin (ots/PRNewswire) - SOLUPORE® technology enables the next-generation of gene-modified cell therapies Irish based cell engineering company, Avectas today announces the publication of 'A novel non-viral delivery method that enables efficient engineering of primary human T cells for ex vivo cell therapy ...

    mehr
  • 11.01.2021 – 13:00

    AVECTAS Appoints Daniel Castro as Chief Business Officer

    Dublin (ots/PRNewswire) - - Newly created role of Chief Business Officer to drive commercialization strategy including partnering SOLUPORE®, Avectas' non-viral cell engineering technology - Daniel Castro brings 25 years of healthcare and pharmaceutical industry experience, with a focus on licensing and deal-making - Based in Boston, MA, at the heart of a major global biotech cluster Avectas, a cell engineering company ...

    mehr
  • 05.11.2020 – 09:00

    Avectas Opens Canadian Development Site

    Dublin (ots/PRNewswire) - - Avectas announces residency at Johnson & Johnson Innovation - JLABS @ Toronto, central to the Canadian bio-hub. - Jessica Schwaber, PhD appointed Scientific Director of Cell and Gene Therapy. Avectas, a cell engineering technology business, is pleased to announce it has been accepted to become a resident at Johnson & Johnson Innovation - JLABS @ Toronto. JLABS @ Toronto is a 40,000 square-foot ...

    mehr
  • 03.06.2020 – 08:00

    Avectas and UC Davis Collaborate on Cell Engineering Technology

    Dublin (ots/PRNewswire) - Collaboration will advance Avectas' cell engineering technology leveraging UC Davis' world-class cell membrane characterisation expertise Avectas today announced that it has entered into a collaborative agreement with The Simon Laboratory at UC Davis, California, USA (UCD) to engage in the characterisation of cells engineered with Avectas' proprietary, non-viral SOLUPORE(TM) cell engineering ...

    mehr